. In the small subset of ART-naive individuals infected with HIV who maintain normal CD4 + T cell counts and immune function and, therefore, do not progress to disease, the mechanisms operating in children and adults are markedly different. Non-progressing adult infection, in so-called elite controllers, is typically characterized by a strong HIV-specific CD8 + T cell response restricted by 'protective' MHC class I molecules (for example, HLA-B27 and HLA-B57) [3] [4] [5] , such that high CD4 + T cell counts are maintained as a consequence of successful suppression of viraemia beneath the levels of detection (normally <50 HIV RNA copies per ml). By contrast, non-progressing HIV-infected children (who are defined here as healthy, ART-naive children aged more than 5 years who maintain absolute CD4 + T cell counts in the normal range for age-matched uninfected children (above 750 cells per mm 3 of blood)) 6 maintain normal CD4 + T cell counts despite median viral loads of ~30,000 copies per ml of plasma 7 , and the HLA-B alleles that strongly influence disease outcome in adult infection do not have a significant role in these children 8 . It is important to clarify the distinction between non-progressing adult and paedi atric infection, which is defined by the maintenance of normal CD4 + T cell counts in the absence of ART, and long-term survivors, who typically have low CD4 + T cell counts and high levels of immune activation 7 , but may be asymptomatic (presenting late) and, in the case of children, are usually stunted 9, 10 . Non-progressing adult and paedi atric infection are both charac terized by low levels of immune activation but through distinct mechanisms. In non-progressing adult infection, this is achieved through HLA-mediated suppression of viral replication. In non-progressing paediatric infection, the mechanism by which immune activation remains low in some patients despite persistent high levels of viraemia 7 is unknown. The phenotype of normal CD4 + T cell counts and low levels of immune activation, despite high viral loads, is reminiscent of the natural hosts of simian immuno deficiency virus (SIV), such as the sooty mangabey and African green monkey, which live normal lifespans with normal CD4 + T cell counts and low levels of immune activation but have median viral loads of ~10 5 SIV RNA copies per ml (REF. 11 ).
The differences that exist between adult and paediatric HIV infection, not only in terms of disease outcome and immune response to HIV but also in terms of mode of transmission, have provided opportunities to improve our understanding of the mechanisms of immune control of HIV. The possibility that these differences might also provide opportunities to learn about mechanisms of HIV eradication or 'cure' was initi ally prompted by the report of the 'Mississippi child' (REFS 12, 13) 
. Although virus levels ultimately rebounded in the Mississippi child 28 months after ART discontinuation, the case was sufficiently unusual to prompt the hypothesis that the early initiation of ART during paediatric infection might provide the setting in which HIV eradication, or remission, could most readily be achieved.
Antiretroviral therapy
(ART). The combination of usually a minimum of three anti-HIV drugs that aim to suppress viral replication, slow disease progression and minimize the risk of transmission. Pre-exposure prophylactic ART has also been shown to protect against HIV infection.
CD4 + T cell counts
The number of T cells expressing the CD4 receptor on their surface in a microlitre of blood. These white blood cells 'help' the immune system to mount a response against pathogens and are the main target cells of HIV infection.
Time since infection Time since infection
Time since infection Viral load (copies per ml) Viral load (copies per ml) Viral load (copies per ml) Viral load (copies per ml)
Typical (progressing) adult infection Typical (progressing) paediatric infection
Viral set point Viral set point
Non-progressing adult infection Non-progressing paediatric infection
Time since infection Declining CD4 + T cell count; high levels of immune activation A further anecdotal example of post-treatment control of viraemia was recently described in a French HIVinfected child
. Although anecdotal cases can be misleading
, this paediatric example follows the description of post-treatment control in the VISCONTI cohort of adults who received ART during acute infection (within months, not days, of infection) and who discontinued ART after a median of 3 years 14 . It is estimated that 5-15% of adults who initiate ART in early infection and continue for this duration become post-treatment controllers, but the equivalent figure in paediatric infection following early initiation of ART is unknown. Several reports have described viraemic rebound within days of ART discontinuation in children in whom ART was initiated in the first week of life and continued for 2-4 years [15] [16] [17] [18] . In the much larger CHER study, in which 250 children were treated for either 40 or 96 weeks from a median age of 7 weeks 19 , and in the PEHSS study 20 , in which 19 infants received 12 months of ART from a median age of 4 weeks, all patients rebounded soon after ART discontinuation (M. F. Cotton, personal communication; P.J.G., unpublished observations). In summary, it is not currently known whether early initiation of ART in paediatric infection is more or less likely to facilitate post-treatment control than early initiation of ART in adult infection.
This Review considers the probable impact of early initiation of ART on the potential for HIV eradication in children versus adults and discusses the influence of immune ontogeny and maternal transmission in paedi atric infection. Finally, we consider the particular opportunities that these features of paediatric infection present in terms of strategies to promote HIV remission or eradication. Typical, progressing adult and paediatric infection (upper panels), and non-progressing adult and paediatric infection (lower panels) 2, 7, 8, 161 . Typically, in HIV infection of antiretroviral therapy (ART)-naive adults, a viral set point is reached after 6 weeks, and the median time to AIDS is 10 years. In typical, ART-naive paediatric infection with HIV, a viral set point is reached after 5 years, and the median time to AIDS is 1 year. Non-progressing adult infection is characterized by low or undetectable viral loads and low levels of immune activation. The prevalence of non-progressing paediatric infection is 5-10% 7,162,163 and of adult elite controllers is ~0.3%
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. Non-progressing paediatric infection also features low levels of immune activation but in the setting of high viral loads (~30,000 copies per ml). Early ART in paediatric versus adult infection Feasibility. In adult infection, outside of expensive trial settings 21, 22 , the identification of early HIV infection is problematic. By contrast, in utero paediatric infection, which mainly occurs late in the third trimester 23, 24 , can be diagnosed using point-of-care testing 25 within hours of birth in the children of chronically HIV-infected mothers, and ART can be initiated in these children within minutes of birth, pending the results of diagnostic tests. In most cases, therefore, treatment can be started earlier in paediatric infection than in adult infection. However, in some cases -for example, when the mother develops acute infection during pregnancy 16 -in utero transmission can occur several weeks before birth (FIG. 2) . In addition, paediatric infection can arise from intra-partum or post-partum mother-to-child transmission (MTCT), and in neither case are these infections detectable at birth. Furthermore, there are added challenges to detecting intra-partum or post-partum infection for the practical reason that the mother and child have long departed the hospital. Therefore, initiating ART soon after infection following intra-partum or post-partum transmission of HIV may be substantially more difficult than after in utero transmission that mostly arises late in the third trimester and is detectable at birth. However, it is not known whether the timing of early initiation of ART during infection is crucial to the outcome in terms of post-treatment control. On the one hand, SIV-macaque studies indicate that there is a very rapid seeding of the viral reservoir, within 3 days of infection 26 . On the other hand, in the VISCONTI cohort subjects, ART was initiated within the first 2-3 months of infection -which is categorized on the basis of Fiebig stages I-VI 27 -similarly as in the VISCONTI teenager 28 , which indicates that ART initi ation after the first few days of infection does not preclude subsequent post-treatment control in HIV infection.
Viral reservoir
Reduction of the viral reservoir. It is evident that early initi ation of ART reduces the frequency of latently infected T cells in both adult and paediatric infection. If ART is initiated during chronic infection in adults, the latently infected resting CD4 + T cells persist with a halflife of 44 months [29] [30] [31] . However, treatment of adults during acute infection results in an approximately 10-100-fold lower frequency of latently infected resting CD4 + T cells compared with chronic infection, when measured in terms of either HIV DNA or replication-competent virus [32] [33] [34] . Similar results have been demonstrated in SIVinfected macaques when treatment is initiated within 3 days compared with 7 days after infection 26 . In addition, the amount of cell-associated unspliced HIV RNA, which reflects basal levels of HIV transcription, is significantly lower in individuals who are treated in acute infection compared with chronic infection 35 . Much of the decrease in HIV DNA and unspliced HIV RNA levels occurs in the first few years of therapy 36, 37 . Latently infected CD4 + T cell subsets have different decay rates, and following long-term ART (more than 10 years), long-lived central memory T cells, memory stem cells and naive T cells are the main T cell subsets enriched with HIV 36, 38, 39 .
In infants who received ART at a median age of 8 weeks, the half-life of latently infected resting CD4 + T cells was 11 months during the first 2 years on ART 40 . Levels of both cell-associated HIV DNA and cellassociated HIV RNA are lower in children in whom ART was initiated earlier after infection 17, [41] [42] [43] [44] . In the CHER study, for example, in which levels of both HIV DNA and cell-associated HIV RNA were measured, initiation of ART in children before 2 months of age (at a median age of 53 days) resulted in a lower frequency of HIV-infected CD4 + T cells 7-8 years later, compared with children in whom ART was started at more than 2 months of age (at a median age of 170 days) 43 . Furthermore, whereas the levels of cell-associated HIV DNA seem to plateau after ~4 years in adult infection 45 , in children these levels continue to decline for more than a decade 41 . Treatment of HIV infection in children at a median age of 2 months resulted in a significant decrease in HIV DNA, but the persistence of 2-LTR circles (2-long-terminal repeat circles) and cell-associated unspliced RNA after 96 weeks, and the frequency of HIV DNA was more than 148-fold higher than the frequency of infectious genomes 46 , as previously described following treatment of HIV in adults 47 . Thus, ART can generally be initiated earlier in paediatric in utero infection than in adult infection, the half-life of latently infected resting CD4 + T cells is shorter in children, and initial studies indicate that decline in the viral reservoir seems to continue for longer in children than in adults on ART.
Box 1 | Case studies of the Mississippi child and the VISCONTI child
The Mississippi child The 'Mississippi child' (REFS 12, 13) was infected with HIV in utero, and antiretroviral therapy (ART) was initiated at 30 hours of age and continued for the first 18 months of life; viral load remained undetectable for more than 2 years following ART discontinuation.
Other unusual aspects of this case were: • The healthy CD4 + T cell count (644 cells per mm 3 ) and low viral load (2,423 copies per ml) of the ART-naive mother (the median viral load of in utero-transmitting HIV-infected mothers is ~90,000 copies per ml (REF.143)).
• The low viral load (19,812 copies per ml at 30 hours post-delivery) of the child (the median viral load of in utero-infected infants is ~150,000 copies per ml on the first day of life) 143 .
• The high percentage (69%) of lymphocytes that are CD4 + T cells 8 days post-delivery (in HIV-uninfected infants, the median percentage of CD4 + T cells is 52%) 6, 143 .
• Viral rebound in the absence of HIV-specific immune responses in the child to a steadystate value of only 16,750 copies per ml, which is similar to the pre-ART viral load.
The VISCONTI child
The 'VISCONTI child' (REF. 28 ) received ART for the first 6 years of life, probably following intra-partum infection (HIV DNA and HIV RNA were undetectable at 3 days of age) and has remained aviraemic (less than 4 copies per ml) for 12 years so far since ART discontinuation.
Other unusual or notable aspects of this case were: • ART (3-4 drugs) was initiated at 3 months of age, at which time the viral load was 2.17 × 10 6 copies per ml.
• Two separate episodes of ART non-adherence in the second year of life resulted in viral rebounds to 50,000-100,000 copies per ml.
• After ART discontinuation, there were no apparent increases in viral load other than to 510 copies per ml at 11 years old and 48 copies per ml at 13 years old.
• Infection was with a rare clade of HIV, subtype H, the significance of which is unknown.
Cell-associated unspliced HIV RNA
Unspliced HIV RNA is detected in cells of individuals on antiretroviral therapy (ART) from the initial first step of long-terminal repeat-mediated HIV transcription before splicing, host promoter-initiated HIV transcription (or read-through transcription) or virus production. By contrast, plasma HIV RNA measures RNA in mature virus particles.
2-LTR circles
(2-long-terminal repeat circles). Circularized forms of unintegrated viral DNA that are by-products of HIV DNA integration into the host genome and exist only in the nucleus. The stability of 2-LTR circles is controversial, but they are generally thought to be short-lived.
Impact of immune ontogeny on cure potential
Several aspects of normal development will have an important influence on the establishment and size of the viral reservoir, some of which are likely to increase, and others to decrease, the potential for HIV cure in infected children. The overall balance of these effects may depend crucially on the timing of ART initiation following birth.
Tolerogenic environment in early life. The immune system in utero and in early life is exquisitely adapted to meet the particular challenges of that phase of life. In utero, the need to avoid making inflammatory responses during the frequent exposure to noninherited maternal antigens is facilitated by the high levels of transforming growth factor-β (TGFβ) in the fetus that direct the peripheral differentiation of naive T cells, in the presence of the cognate antigen, into 'adaptive' regulatory T cells (T Reg cells) 48 . These memory T Reg cells are long-lived and can be found in children aged 7-17 years 48 . T Reg cells make up 15% of fetal blood T cells, compared with ~5% of adult blood T cells 49 . Moreover, innate immune cells at birth, compared with adulthood, respond to a panel of Toll-like receptor (TLR) agonists by secreting higher levels of interleukin-6 (IL-6), IL-1β and IL-23, which support T helper 17 (T H 17) cell differentiation, and lower levels of pro-inflammatory cytokines such as type I interferons (IFNs), and hence lower levels of IFNγ, tumour necrosis factor (TNF) and IL-12, which support T H 1 cell differentiation [50] [51] [52] . The higher levels in neonates of immunoregulatory and anti-inflammatory cytokines (such as IL-10 and TGFβ) and of T H 2 cell-supporting cytokines (IL-4, IL-5, IL-9 and IL-13) 53 ,54 further function to dampen down T H 1 cell responses. Finally, plasma levels of adenosine are higher in neonates than in adults and may contribute to the T H 17 cell bias and low levels of immune activation in early life through increased IL-6 synthesis and decreased TNF production 51 . The immune response in utero and in early life therefore establishes a tolerogenic environment that is broadly anti-inflammatory and that promotes T H 17 cell-mediated host defence against extracellular bac terial and fungal pathogens, at the expense of a strong T H 1 cell-driven response which, by contrast, is a feature of antiviral cell-mediated immunity in adults.
In the setting of HIV infection in early life, one effect of these immune adaptations is to eliminate the possibility of HLA class I-restricted CD8 + T cell-mediated suppression of viraemia that is observed in adult elite controllers. However, the tolerogenic environment in early life favours low levels of immune activation, which could interfere with the vicious cycle that normally occurs during adult infection of immune activation, increased bystander cell death through apoptosis and pyroptosis 55, 56 , increased susceptibility of activated CD4 + T cells to further infection and increased virus production (FIG. 3) . For similar reasons to those hypothesized in adult post-treatment controllers who express disease-susceptible HLA alleles such as HLA-B35 (REF. 11) (discussed further below), the tolerogenic environ ment of early life may interfere with the establishment of latent infection in the long-lived naive, stem cell-like memory and central memory CD4 + T cells. There is some suggestion that early treatment of children, in contrast to adults, can result in lower levels of these latently infected long-lived T cell subsets 36, 41 . Reduced infection of long-lived T cell subsets has also been observed in adult post-treatment controllers and elite controllers 14 .
Role of T H 17 cells.
A factor that may also affect the ability of HIV to establish long-lived latency is the high proportion of naive CD4 + T cells in utero and in newborns. Indeed, in cord blood, there are almost no activated CC-chemokine receptor 5 (CCR5)-expressing memory CD4 + T cells 57 . CCR5 is the co-receptor by which HIV gains entry into CD4 + T cells, and activated memory CD4 + T cells expressing CCR5 are the most susceptible targets for HIV infection [58] [59] [60] . By contrast, in the intestinal epithelium in utero and at birth, almost one-third of the CD4 + T cells express CCR5, many of which also express CCR6 (REF. 54 ), which is characteristic of T H 17 cells that are highly permissive for HIV infection 61, 62 . Even resting CD4 + T cells that express CCR6, in the presence of the CCR6 ligand CCL20, have an increased susceptibility to direct infection and establishment of HIV latency 63 . Thus, the theoretical paucity of CD4 + T cell targets for HIV infection in utero and early life is at least partly compensated for by the high numbers of T H 17 cells and other CD4 + T cell targets available in the intestinal epithelium.
It is of note that the immune system at birth has a strong T H 17 cell bias, given the importance of T H 17 cells both functionally, in host defence against extra cellular pathogens, and structurally, in maintaining the integrity of the intestinal mucosal barrier 64 . Microbial translocation has a central role in the vicious cycle of immune Long-term aviraemia following early ART and ART discontinuation in an HIV-infected adult. The original 'Berlin patient' was described in 1999 (REF. 144 ) (not to be confused with the more famous Berlin patient, Timothy Ray Brown, who was cured of HIV infection following a stem cell transplant from a donor homozygous for the CC-chemokine receptor 5 (CCR5) Δ32 deletion); suppression of viraemia was achieved after initiation of antiretroviral therapy (ART) during acute HIV infection, and for 15 years after ART discontinuation, the viral load remained at low to undetectable levels (median viral load of 399 copies per ml) 145 . Only recently has it emerged that this subject expressed HLA-B57. The existence of a subset of ART-naive, HIV-infected adults termed elite controllers (FIG. 1) was not well described in the 1990s; however, it is now known that 40-50% of elite controllers express HLA-B57 (REF. 146 ). Therefore, a major factor in immune control in the case of the original Berlin patient may have been the expression of HLA-B57.
Long-term aviraemia following early ART and ART discontinuation in an HIV-infected child. ART (with didanosine and zidovudine) was initiated at 18 months of age in a child testing HIV-positive in 1991. For the next 8.5 years, viral loads were undetectable (less than 400 copies per ml) while the patient was on therapy. ART was discontinued at the age of 10 years, and, with the exception of intermittent increases in viraemia that never exceeded 1,000 copies per ml, viral load remained undetectable for the next 5 years until the case was reported 147 . The HLA type of this child did not include 'protective' HLA alleles. However, the child was heterozygous for the CCR5Δ32 mutation, which has been shown to delay disease progression in both adult and paediatric HIV infection. activation that results in CD4 + T cell decline during HIV infection, and the preferential loss of T H 17 cells observed in HIV infection 65 is therefore likely to have a disproportionate impact on paediatric infection. It is noteworthy that, despite substantial loss of intestinal CD4 + T cells following acute SIV infection in both natural 66, 67 and experimental hosts [68] [69] [70] , T H 17 cell numbers in the gut are maintained at normal levels in non-pathogenic SIV infection 71 . The presence of higher levels of adenosine in mucosal tissues in non-pathogenic infection 72 indicates that the adenosine pathway may contribute to limiting T H 17 cell loss by reduced immune activation and the promotion of T H 17 cell differentiation. In adult HIV infection, if ART is initiated sufficiently early, T H 17 cell numbers are preserved and/or restored, and levels of systemic immune activation are normalized 22 . Thus, the preferential loss of T H 17 cells in the intestinal mucosa during HIV infection in utero and in early life may have a disproportionate impact on that age group, leading to increased susceptibility to infections with extracellular pathogens, microbial translocation and immune activation. Therefore, the timing of early ART in paediatric infection may be particularly important.
Increased immune activation in early life. Working against the tolerogenic environment are factors that predispose to increased immune activation in early life. This is directly relevant to the reservoir size because increased immune activation increases viral replication (FIG. 3) . For example, microbial translocation across the intestinal barrier is increased in neonates, whether HIV infected or not 73, 74 . This is particularly true for premature infants, and more than one-third of babies born to HIV-infected mothers are premature (that is, born before 37 weeks of gestation). The changing composition of the intestinal microbiota also contributes to higher levels of immune activation in early life 73, 75 . It is proposed that mixed feeding, as opposed to exclusive breastfeeding, predisposes to increased risk of gastrointestinal infections and mucosal inflammation and, therefore, an increased risk of HIV transmission through breast milk 76, 77 . Microbial translocation, leading to increased immune activation, is similarly increased by breaches in the intestinal mucosa, and thus it is reasonable to assume that the type of feeding received by the child may in this way strongly influence the establishment and size of the viral reservoir before ART initiation in the infant.
Immune activation can also be increased by vaccinations and new infections that are common in infancy. The immunization schedule provides crucial protection against diseases to which HIV-infected children may be particularly susceptible, but certain vaccines may also have unwanted side effects. Mycobacterium bovis bacille Calmette-Guérin (BCG) is a particular case in point 78 . BCG, which is given at birth to all South African infants on the first day of life, protects against miliary tuberculosis (miliary TB) and TB meningitis 79 , and it may also have non-specific benefits in terms of reducing morbidity resulting from non-mycobacterial infections 80 . However, the increased levels of immune activation that result from BCG vaccination increase HIV infection risk in uninfected infants and increase disease progression in infected infants 78 . Among the large number of infections to which newborns are exposed, cytomegalovirus (CMV) is noteworthy both for its effect in increasing immune activation 81 and its prevalence in countries in which HIV is abundant. By 3 months of age, almost two-thirds of children in sub-Saharan Africa have become infected with CMV 81 . CMV coinfection in HIV-infected children results in more rapid HIV disease progression 82 . All of these factors that function to increase immune activation in early life may oppose the benefits in terms of HIV infection and disease progression that would be expected to result from the tolerogenic immune environment in early life described above. However, initiation of ART in the first 24-48 hours of life, before many of these factors have maximum effect, would markedly reduce their impact.
Differential localization of viral reservoirs.
In adults on ART, HIV-infected T cells are found at higher frequency in the gastrointestinal tract and lymph nodes than in the blood 83, 84 . A detailed comparative analysis of other tissue Mother-to-child transmission (MTCT) risk of HIV in the absence of prophylactic measures is approximately 7% from in utero infection, 18% from intra-partum infection and 15% from post-partum transmission (through breast milk from breastfeeding for 18-24 months) [164] [165] [166] [167] . In utero HIV-infected infants are viraemic and HIV DNA-positive at birth, whereas transmission arising at the time of delivery (intra-partum) results in viraemia approximately 4 weeks later. Treatment with antiretroviral therapy (ART) of all mothers testing HIV-positive in pregnancy has reduced combined in utero and intra-partum MTCT from 25% to 1-2%
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, and prevention of breast-milk transmission through ART of the mother has reduced post-partum MTCT rates to 1-2%
168
. The remaining 1-2% MTCT rate results either from ART non-adherence or from acute infection during pregnancy or after birth (in utero MTCT risk of ~20% 167, 169, 170 or post-partum MTCT risk of 20-25%
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) as tests to detect HIV antibody are negative during acute maternal infection when peak viraemia is ~10 7 copies per ml and transmission risk is high. 88 , as alveolar macrophages in the lung 89 and as microglia or perivascular macrophages in the central nervous system (CNS) 90 . HIV latency has also been demonstrated in astrocytes in the CNS 91 . It is not clear whether HIV DNA that persists in tissue macro phages is replication competent and contributes to viral rebound following cessation of ART.
In HIV-infected children, the location of latently infected T cells or tissue macrophages has not been explored but may be quite different, given the low frequency of memory T cells and different levels of expression of key chemokine receptors. Although detecting HIV persistence in tissues is challenging, recent novel methods developed in the macaque model, such as total-body imaging 92 and RNAscope or DNAscope in situ hybridization, should aid future studies of HIV persistence in children on ART. This is an important feature to understand, as the mechanisms that lead to HIV persistence in resting T cells and macrophages differ 93 , and, therefore, strategies to activate or eliminate infected cells will need to be different. This has recently been demonstrated in terms of the ex vivo response to histone deacetylase (HDAC) inhibitors of virus derived from brain tissue compared with spleen 94 . Finally, many recent papers have shown that the majority of HIV DNA measured in blood CD4 + T cells from HIV-infected individuals on ART is replication defective 47, 95 . Furthermore, the conventional viral outgrowth assay may underestimate the true number of cells that carry replication-competent virus owing to the presence of intact proviruses that are not induced through T cell stimulation 96 . In a single recent study in children treated with ART, it seems that there is a similar relationship between intact and defective viruses in children as in adults 46 , but more studies are required in children using newer molecular strat egies to define the relationship between defective and replication-competent virus in this setting. + T cell loss -can be prevented by the initiation of antiretroviral therapy (ART) sufficiently early in adult and paediatric infection. There are factors specific to paediatric infection that tend to interfere with this vicious cycle, and others that contribute to it, the balance of which may vary between individuals and also may depend crucially on the timing of ART initiation. Aspects of immune ontogeny that favour decreased immune activation include the tolerogenic immune environment in utero and in early life and the high proportion of naive CD4 + T cells. Aspects of immune ontogeny that tend to decrease paediatric cure potential include the large number of T helper 17 (T H 17) cells in the intestinal mucosa. Maternal factors that favour paediatric cure potential include maternal health, exclusive breastfeeding, lack of co-infections and expression of HLA class I molecules that bind leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2) with high avidity. BCG, bacille Calmette-Guérin; CMV, cytomegalovirus; IFN, interferon; IL, interleukin; TB, tuberculosis; TGFβ, transforming growth factor-β; TNF, tumour necrosis factor; T Reg cell, regulatory T cell.
Phambili trial
A trial that tested the efficacy of the MRKAd5 subtype B HIV-1 Gag/Pol/Nef vaccine in South Africa, where subtype C virus is dominant. The vaccine increased the risk of HIV acquisition and did not reduce early viraemia.
Escape mutants
Viral variants that reduce recognition by the immune system, typically arising in epitopes that are targeted by HIV-specific CD8 + T cells or neutralizing antibodies.
T cell vaccine potential. Children who have received ART in the first few days of life often subsequently lack detectable HIV-specific immune responses. Western blot non-reactivity has been proposed as a marker of early and profound suppression of viral replication 41 , and lack of HIV-specific cellular immunity may be similarly indicative. However, it is well established that HIV-specific CD8 + T cell responses are evident at birth in the majority of children infected in utero 97, 98 . This suggests that rapid removal of the HIV antigen in infancy or early childhood may result in loss of the memory response even though an immune response was induced. Thus, in early ART-treated HIV-infected children, there may be the potential for a T cell vaccine to skew the CD8 + T cell immunodominance pattern in a more favourable direction -such as towards a broad Gag-specific response -than would be the case if the pre-existing, suboptimal T cell responses that are generated in natural infection are predominant.
Successful skewing of the natural immunodominance pattern of the CD8 + T cell response by an HIV T cell vaccine has been demonstrated in recent analyses of participants in the South African Phambili trial 99 who subsequently became infected. In individuals expressing the disease-susceptible HLA-B*5802 allele, recipients of the MRKAd5 HIV-1 Gag/Pol/Nef vaccine made broader and higher magnitude Gag-specific responses than HLA-B*5802-positive recipients of a placebo 100 . The placebo recipients showed the Env-dominated response pattern that is typical of natural infection 101 . In association with skewing of the CD8 + T cell response towards targeting Gag, viral set points in the HLA-B*5802-positive vaccine recipients were significantly lower than in the HLA-B*5802-positive placebo recipients 100 . In summary, a range of factors associated with the developmental stage of the child at which HIV infection occurs, before ART is initiated, are likely to affect markedly the ultimate size of the HIV reservoir. The overall effect of these mixed influences might depend crucially on the exact timing of in utero HIV transmission and of ART initiation. It is probable that if ART can be initiated within the first 24-48 hours of life, then the factors predisposing to increased microbial translocation and increased immune activation would be largely mitigated, thereby providing children with an inherent advantage compared with adults in terms of the potential for HIV cure.
Impact of maternal factors on cure potential
In utero and intra-partum MTCT are effectively prevented entirely if viraemia is suppressed by ART during pregnancy. In countries such as South Africa, prevention strategies have reduced MTCT rates that arise in utero or intra-partum from 25-30% without any therapy to 1-2% currently 102 . When transmission does occur, this tends to be associated with challenging circumstances. For example, more than 60% of transmitting mothers in South Africa have a daily income of less than US$1, the source of water in more than one-third of cases is either a shared standpipe or river water, and toilet facilities for almost one-half of mothers are a pit latrine 20 . In these settings in particular, the outcome of the child may have less to do with immunology than with the physical and mental well-being of the mother and the presence or absence of a social support network. There are therefore practical aspects of successful HIV treatment that differ between adults and children, and the dependence of an infected child on the mother to administer ART, in addition to the other needs of childhood, is an added challenge that should not be underestimated.
Maternal HLA type. The risk of MTCT is strongly related to maternal viral load 103, 104 , and therefore transmitting mothers are more likely to express HLA class I molecules that are known to be associated with high viral set points and rapid progression to disease 105, 106 . In African populations, these are HLA-B*1801, HLA-B*4501 and HLA-B*5802. In Caucasian populations, the best-studied example is HLA-B35. As children inherit one HLA haplotype from their mother, in utero HIV-infected children, as a group, are enriched with the HLA class I molecules that are associated with rapid progression in adult infection 106 . However, as described above, the HLA-B alleles that have a substantial impact on adult infection do not significantly influence paediatric disease outcome 8 . Indeed, it has been proposed that HLA class I molecules such as HLA-B35 that are associated with rapid disease progression in adults may actively facilitate post-treatment control 14 . A possible mechanism is suggested by the fact that HLA-B35 and HLA-B*4501 bind leukocyte immunoglobulinlike receptor subfamily B member 2 (LILRB2) with high avidity, whereas protective HLA alleles such as HLA-B27, HLA-B57 and HLA-B*5801 bind LILRB2 with low avidity 107 . LILRB2 is expressed on cells of the myeloid lineage, such as conventional dendritic cells, and high-avidity HLA class I binding to LILRB2 inhibits dendritic cell function. The failure of disease-susceptible HLA class I molecules such as HLA-B35 to induce broad HIV-specific CD8 + T cell responses in adult infection, leading to high viral set points, may therefore in part be due to the inhibitory action of LILRB2 on dendritic cell activity. However, in the setting of early initiation of ART, factors such as these that reduce antiviral T cell immunity may tend to reduce immune activation and thereby influence the establishment and cellular localization of the latent HIV reservoir. If this proves to be the case, the apparent maternally inherited HLA 'handi cap' in infected children may in fact predispose towards post-treatment control following early ART.
Virus type transmitted through MTCT. One of the bene fits of early initiation of ART in paediatric and adult infection is to suppress viral replication before the selection of autologous escape mutants. The early initiation of ART might be particularly important in adults, in whom cytotoxic T lymphocyte (CTL) escape mutants are selected from the first few weeks of infection 108 and persist in latently infected T cells 109 . By contrast, CD8
+ T cell responses in in utero HIV-infected infants, even when restricted by protective HLA alleles,
Broadly neutralizing antibodies
HIV-specific antibodies that arise during natural infection in 10-30% of individuals and can effectively neutralize diverse viral isolates.
Step trial such as HLA-B57, HLA-B*5801 and HLA-B*8101, seem to be insufficiently functional in the first few months of infection to select virus escape mutants 8 . However, in MTCT, the virus that is transmitted is in many cases pre-adapted to T cell responses available in the child, as well as to maternal antibodies crossing the placenta. As the child inherits half of the mother's HLA alleles, in theory the virus transmitted from mother to child may be pre-adapted to all of the CD8 + T cell epitopes that are restricted by the HLA alleles shared with the mother 110 . However, for two reasons, this may be less of a problem in reality. First, the mothers of children infected with HIV tend to express disease-susceptible HLA alleles 106 (as described above), and these typically do not select any virus escape mutants in the crucial Gag epitopes 111 . Second, as prevention of MTCT becomes increasingly effective, the proportion of in utero transmissions that result from acute infection of the mother during pregnancy becomes greater (FIG. 2) . In this scenario, in utero transmission may occur before escape mutants have been selected in maternal virus.
In summary, the mother has a crucial role in determining morbidity and survival of the child. However, if an HIV-infected mother is healthy and sufficient health-care support is available for mother and child, there are reasons to believe that the inheritance by the child of maternal disease-susceptible HLA alleles and the transmission of HIV adapted to maternal immune responses may not be a major disadvantage in relation to the potential for HIV cure in children versus adults.
Opportunities for effective cure strategies Several factors discussed here provide a rationale for the proposition that unique possibilities exist to facilitate the eradication or remission of HIV in children, namely: the feasibility of initiating ART within 24-48 hours of birth; the ability of ART to make faster reductions in the size of the viral reservoir that continue for longer in infants compared with adults; and the ability of ART to minimize the effect of factors in early life that would otherwise counteract the reduced immune activation resulting from a tolerogenic environment. However, there are also specific obstacles that narrow both the window of opportunity and the range of immunotherapeutic interventions that can be used in children. In particular, the very poor levels of ART adherence in adolescence 112 , coupled with the normal onset of adolescence as early as 8 and 9 years of age in females and males, respectively 113, 114 , effectively place a time limit on the age by which immunotherapeutic interventions need to be in place (FIG. 4) .
Early ART alone. The universal failure, so far, of ART initiated in the first few weeks of life to result in post-treatment HIV control in paediatric infection, let alone cure, may indicate that ART should be initiated even earlier and/or for a longer duration and that there may be additional interventions, other than those related to the timing of onset and duration of ART, that are likely to be required to achieve post-treatment control. Host genetic factors may contribute to the likelihood of post-treatment control, as has been proposed in the VISCONTI adult cohort in relation to HLA class I type. Defining these factors will require large studies to initiate early ART in sufficient numbers of in utero HIV-infected infants to eliminate some of the misleading conclusions that can arise from anecdotal cases
Broadly neutralizing antibodies at birth. Broadly neutralizing antibodies do not typically neutralize contemporaneous autologous virus 115 and tend to be isolated in HIV-infected individuals who have high viral set points and are progressing to AIDS 116 . Maternal antibodies crossing the placenta do not neutralize transmitted virus or affect paediatric disease progression 117 . However, heterologous broadly neutralizing antibodies can both prevent infection 118, 119 and enhance subsequent B cell responses in infected infants 120 , and they also substantially reduce viral replication in simian-human immuno deficiency virus (SHIV)-infected macaques (PGT121 antibody) 121 and in HIV-infected humans (3BNC117 antibody) 122 . Expression of broadly neutralizing antibodies by adeno-associated virus vectors 123 has the potential to prevent infection for life, although longterm protection against infection using this approach has only been demonstrated in animal models so far 124, 125 . In paediatric infection, broadly neutralizing antibodies could be used at birth at the same time as ART is initiated (FIG. 3) . Human monoclonal antibodies protected against SHIV infection following oral challenge in neonatal macaques 126 . This approach, in combination with ART, may potentially reduce viral loads by 1-2 log 10 over 7-10 days after infusion 127 in addition to the effect of ART. ART alone can reduce a typical starting viral load of 10 5 -10 6 copies per ml to less than 50 copies per ml in 3-6 months 20 , whereas ART in combination with a broadly neutralizing antibody might achieve aviraemia in days or weeks. The timing of ART initiation and the time to viral suppression are both important independent factors that influence the ultimate size of the latent viral reservoir 44 . Early suppression of viraemia clearly limits the size of the reservoir but importantly may also limit viral diversity, which thereby might increase the efficacy of any immunotherapeutic approaches that are used later, as described below.
Timing of further immunotherapeutic interventions.
Having initiated ART early and achieved suppression of viraemia, sufficient time should then elapse before the introduction of further immune interventions: first, to enable the latent viral reservoir to be optimally reduced to levels beneath the level of detection of the most sensitive assays; and, second, to allow T H 1 cell-polarizing innate immune responses to develop more fully, for the reason that cell-mediated immunity is likely to have a key role in eradication of the viral reservoir 109 . Although IL-12, a T H 1 cell-polarizing cytokine, remains at lower levels in infants than in adults (even in 12-year-old children) 52 , by 2 years of age levels of type I IFNs are similar to those in adults, levels of IL-6 and IL-23 (T H 17 cellpolarizing cytokines) and of IL-10 (an immunoregulatory cytokine) are lower than in neonates, and T Reg cell numbers are similar to those in adults 128 . Indeed, there is evidence that the middle years of childhood represent a 'honeymoon period' (REF. 129 ), during which the immune response is optimally adapted against a range of infectious agents, including TB, influenza, malaria, Epstein-Barr virus, varicella zoster virus, mumps, measles and perhaps also HIV, such that it is sufficient to control the infection without causing immuno pathology. This period -from approximately 3 to 9 years of agemay therefore be the optimal window of opportunity for immunotherapeutic interventions designed to facilitate HIV eradication, before the onset of adolescence (FIG. 3) .
T cell vaccines. Early generation T cell vaccines did not reduce viral loads overall in vaccine recipients, and the adenovirus type 5 (Ad5) vector used in the Step trial and Phambili trial was associated with increased risk of infection 130 . However, current approaches such as those using prime-boost regimens of chimpanzee adeno virus and modified vaccinia virus Ankara result in T cell responses that are 1 log 10 higher in magnitude and 5-10-fold greater in breadth compared with the T cell responses achieved by MRKAd5 HIV-1 Gag/ Pol/Nef 131,132 (B. Mothe, personal communication).
The safety and immunogenicity of these prime-boost approaches have been established in Phase I and Phase II trials of malaria vaccination in children ranging in age from infants (10 weeks old and 5-12 months old) to mid-childhood (2-6 years old) (K. Ewer, personal communication). The induction of protective and broad Gag-specific CD8 + T cell responses in children treated early by vaccination and/or the use of broadly neutralizing antibodies could provide the long-term antiviral immunity that is necessary to contain or even to eliminate viral replication from previously latently infected cells, once ART is discontinued.
Latency reversal. Several compounds have now been shown to activate latent HIV infection in vitro 133 . These include epigenetic modifiers, protein kinase C agonists and TLR agonists. HDAC inhibitors were the first latency activators to move into clinical trials in HIV-infected individuals on ART; these studies all demonstrated an increase in cell-associated HIV RNA and, in some studies, an increase in plasma HIV RNA, but no study reported a change in the frequency of latently infected cells [134] [135] [136] [137] [138] . Although HDAC inhibitors have been widely used for the management of malignancy in adults, there is very little , and T helper 1 (T H 1) cell responses take some years to develop fully, a period of time on ART alone may be useful to minimize the size of the viral reservoir before further interventions that are designed to eradicate infection. In late childhood, approximately between the ages of 3 and 9 years, immune ontogeny favours the generation of effective CD8 + T cell immunity, which provides a window of opportunity for therapeutic intervention before the onset of puberty with associated behavioural changes, including loss of ART adherence and onset of sexual activity.
Introduction of additional antiretroviral drugs to a standard three-drug suppressive regimen.
experience in paediatric cases, and the sustained changes in host gene expression that result from their use would be a serious safety concern in children 136 . More recently, disulfiram, which has been in clinical use for decades and with an excellent safety profile, was shown to also activate HIV latent infection 139 . This agent could potentially be evaluated in children for latency reversal. It remains unknown whether there are factors that would alter the susceptibility of latently infected cells from HIV-infected children on ART to activation. This needs to be evaluated in ex vivo studies to ensure that there are no inherent differences in the stability of main tenance of HIV latency in children compared with adults, before the initiation of clinical trials of latency reversal in children.
Other immunotherapeutic strategies. Several additional approaches are currently being developed in adults; some of these show great promise, but their efficacy and safety profile in children have yet to be determined. These are summarized in BOX 3.
Conclusions
The immune system in utero and in early life favours low levels of immune activation, at least initially, following HIV infection. However, in most cases, it seems that ART would need to be initiated as early as possible to minimize the size of the latent viral reservoir and provide a realistic base from which additional immunotherapeutic interventions can be introduced. The timing of their introduction and of a subsequent treatment interruption remain very much open to discussion. In children, as distinct from adults, there is a relatively narrow window of opportunity between the development of an immune response that is sufficient to eliminate activated HIV-infected cells that previously comprised the latent reservoir and the onset of puberty with its accompanying high levels of ART non-adherence. Recent data suggest that even brief ART interruptions in the absence of HIVspecific immunity can lead to a rapid and irreversible increase in the size of the HIV reservoir 43 , underlying the observation that reservoir size alone does not necessarily predict the time to viral rebound 33, 140 . Defining the factors that determine post-treatment control and identifying biomarkers that can predict which individuals will have prolonged antiretroviral-free remission 141 will require additional work, including clinical trials in children. So far, HIV vaccine trials have been rarely undertaken in children, despite evidence of promising immune responses in children who have been vaccinated 142 . Evaluation of early treated children who receive immunotherapeutic interventions should be a priority.
Box 3 | Other potential immunotherapeutic strategies in children
In addition to the early initiation of antiretroviral therapy (ART) and the use of broadly neutralizing antibodies, T cell vaccines and latency reversal agents, other approaches are currently being developed in adults and may be considered in the future for paediatric use.
Immune checkpoint blockade. Blockade of the immune checkpoint molecules programmed cell death protein 1 (PD1) and cytotoxic T lymphocyte antigen 4 (CTLA4) boosts HIV-specific T cell responses ex vivo 148, 149 . In a recent case study of CTLA4-specific antibody (ipilimumab) in an HIV-infected adult on ART with metastatic melanoma, there was a significant increase in cell-associated HIV RNA and a cyclical decline in plasma HIV RNA, which is consistent with enhanced virus clearance 150 .
Treatment intensification. Studies in adults with HIV infection show that treatment intensification has minimal effects on HIV persistence in patients on ART 151 . Two studies that intensified standard ART with raltegravir demonstrated residual virus replication in approximately 30% of individuals 152, 153 .
Anti-inflammatory drugs. Anti-inflammatory agents are being evaluated in HIV-infected adults to determine whether reducing inflammation will reduce HIV persistence -by decreasing either residual viral replication or the number of latently infected cells. Current clinical trials in adults include the anti-inflammatory drugs rapamycin, lisinopril and methotrexate, and antibodies targeting interleukin-1β [154] [155] [156] [157] .
Gene therapy. Gene therapy that uses zinc finger nucleases to eliminate CC-chemokine receptor 5 (CCR5) expression in peripheral circulating T cells was recently shown to be safe in adults, and approximately 6% of the gene-modified cells persisted in blood and tissue 158 . Given safety concerns, it seems unlikely that CCR5 gene therapy will be evaluated in children in the near future. Opportunistic stem cell transplantation from a donor with the CCR5Δ32 mutation could potentially be considered in a child with the appropriate clinical indication, given the success following transplantation of Timothy Brown (the Berlin patient) 159 . However, so far this procedure has not been successful in a further six adults with HIV infection 160 .
